Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 [Globe and Mail, The (Toronto, Canada)]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Globe and Mail, The
This transaction represented 100.00% of Mr. Savitz's direct common stock holdings, reducing his direct and indirect ownership in this class to zero shares. The transaction was structured as an option exercise and immediate sale; only direct holdings were involved, with no participation by trusts or other entities. Mr. Savitz retains 71,776 stock options (right to buy), which can be converted to common stock in the future. On April 9, 2026, Dianthus Therapeutics (NASDAQ:DNTH) Executive Vice President, Chief Financial Officer, and Chief Business Officer Ryan Savitz reported the sale of 8,224 shares of common stock for total proceeds of approximately $739,000, as disclosed in the SEC Form 4 filing . The CFO of this clinical-stage biotech, focused on monoclonal antibody therapies, executed the transaction as an option exercise and immediate sale under a Rule 10b5-1 plan. Transaction summary Metric Value Context Shares sold (direct) Open-market shares sold (code 'S') in
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (DNTH) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Dianthus Therapeutics (DNTH) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Dianthus Therapeutics (DNTH) is now covered by Wolfe Research. They set an "outperform" rating and a $98.00 price target on the stock.MarketBeat
DNTH
Earnings
- 3/9/26 - Miss
DNTH
Sec Filings
- 4/27/26 - Form SCHEDULE
- 4/10/26 - Form 4
- 4/9/26 - Form 144
- DNTH's page on the SEC website